Aldeyra Therapeutics, Inc.

NasdaqCM:ALDX Stock Report

Market Cap: US$108.6m

Aldeyra Therapeutics Future Growth

Future criteria checks 5/6

Aldeyra Therapeutics is forecast to grow earnings and revenue by 65.2% and 57.6% per annum respectively while EPS is expected to grow by 65.3% per annum.

Key information

65.2%

Earnings growth rate

65.32%

EPS growth rate

Biotechs earnings growth25.4%
Revenue growth rate57.6%
Future return on equityn/a
Analyst coverage

Low

Last updated26 May 2026

Recent future growth updates

Recent updates

Analysis Article • Nov 27

Does Aldeyra Therapeutics (NASDAQ:ALDX) Have A Healthy Balance Sheet?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Seeking Alpha • Mar 05

Aldeyra Therapeutics Is Severely Undervalued Before PDUFA

Summary Aldeyra's reproxalap faced an FDA setback but showed positive trial results, leading to a resubmitted NDA with a PDUFA date of April 2025. Despite a controversial deal with AbbVie, Aldeyra remains financially solid, with $100M in cash and potential milestone payments. The DED market is strong, and reproxalap's data surpasses competitors, indicating significant undervaluation of Aldeyra's stock. With a market cap of $368M and promising assets, Aldeyra presents a compelling investment opportunity in the biotech sector. Read the full article on Seeking Alpha
Analysis Article • Feb 06

Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analysis Article • Jun 21

Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Too Much Debt?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
Analysis Article • Feb 16

Is Aldeyra Therapeutics (NASDAQ:ALDX) Weighed On By Its Debt Load?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article • Nov 06

Health Check: How Prudently Does Aldeyra Therapeutics (NASDAQ:ALDX) Use Debt?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analysis Article • Mar 26

Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Earnings and Revenue Growth Forecasts

NasdaqCM:ALDX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20287525-3N/A2
12/31/202720-11-14N/A4
12/31/20262-20-27N/A3
3/31/2026N/A-27-26-26N/A
12/31/2025N/A-34-33-33N/A
9/30/2025N/A-43-40-40N/A
6/30/2025N/A-51-41-41N/A
3/31/2025N/A-58-46-46N/A
12/31/2024N/A-56-43-43N/A
9/30/2024N/A-45-31-31N/A
6/30/2024N/A-38-31-31N/A
3/31/2024N/A-30-31-31N/A
12/31/2023N/A-38-30-30N/A
9/30/2023N/A-46-42-42N/A
6/30/2023N/A-52-47-47N/A
3/31/2023N/A-61-53-53N/A
12/31/2022N/A-62-57-57N/A
9/30/2022N/A-65-57-57N/A
6/30/2022N/A-66-53-53N/A
3/31/2022N/A-63-42-42N/A
12/31/2021N/A-58-43-43N/A
9/30/2021N/A-53-39-39N/A
6/30/2021N/A-46-37-37N/A
3/31/2021N/A-39-36-36N/A
12/31/2020N/A-38-37-37N/A
9/30/2020N/A-39-40-40N/A
6/30/2020N/A-49-42-42N/A
3/31/2020N/A-55-48-48N/A
12/31/2019N/A-61N/A-45N/A
9/30/2019N/A-58N/A-42N/A
6/30/2019N/A-50N/A-41N/A
3/31/2019N/A-46N/A-35N/A
12/31/2018N/A-39N/A-30N/A
9/30/2018N/A-35N/A-27N/A
6/30/2018N/A-29N/A-24N/A
3/31/2018N/A-26N/A-23N/A
12/31/2017N/A-22N/A-19N/A
9/30/2017N/A-20N/A-18N/A
6/30/2017N/A-20N/A-17N/A
3/31/2017N/A-19N/A-15N/A
12/31/2016N/A-19N/A-15N/A
9/30/2016N/A-18N/A-14N/A
6/30/2016N/A-17N/A-14N/A
3/31/2016N/A-15N/A-12N/A
12/31/2015N/A-12N/A-9N/A
9/30/2015N/A-10N/A-8N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ALDX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.5%).

Earnings vs Market: ALDX is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ALDX is expected to become profitable in the next 3 years.

Revenue vs Market: ALDX's revenue (57.6% per year) is forecast to grow faster than the US market (12.7% per year).

High Growth Revenue: ALDX's revenue (57.6% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ALDX's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/26 19:25
End of Day Share Price 2026/06/26 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Aldeyra Therapeutics, Inc. is covered by 17 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Keay NakaeAscendiant Capital Markets LLC
Esther Lannie HongBerenberg
Douglas BuchananBrean Capital Historical (Janney Montgomery)